Benzinga | Mar 2, 2021 07:36AM EST

SVB Leerink Maintains Outperform on FibroGen, Lowers Price Target to $64

SVB Leerink analyst Geoff Porges maintains FibroGen (NASDAQ:FGEN) with a Outperform and lowers the price target from $91 to $64.